As a scientist employed by the FDA, you've been asked to sit on a panel to evaluate a pharmaceutical company's application for approval of a new weight loss drug called Fat Away. The company has submitted a report summarizing the results of their animal and human testing. In the report, it was noted that Fat Away works by affecting the electron transport chain. It decreases the synthesis of ATP by making the mitochondrial membrane permeable to H+ which allows H+ to leak from the mitochondrial matrix to the intermembrane space. This effect leads to weight loss.
The method of weight loss described for Fat Away shows that the drug is acting as a metabolic
A) coenzyme.
B) feedback inhibitor.
C) oxygen carrier.
D) redox promoter.
E) uncoupler.

Uncoupler is the substance that dissociates the chemical reaction occurs in the mitochondria so by doing this it disrupts the process of oxidative phosphorylation which is required to form ATP.

Therefore uncoupler do not allow phosphorylation of ADP to produce ATP by dissipating the proton gradient through regulation of proton channels. As a result the formation of ATP decrease in the cell.

The method of weight loss described for Fat Away include the decreases of synthesis of ATP by making the mitochondrial membrane permeable to H+ shows that the drug is acting as a metabolic uncoupler.

Therefore the correct answer is E) uncoupler.